Reference:
1. Vidal D, Puig L, Gilaberte M, Alomar A. Review of 26 cases of
classical pyoderma gangrenosum: clinical and therapeutic features. J
Dermatol Treat 2004;15(3):146–152
2. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma
gangrenosum: a comprehensive review. Am J Clin Dermatol 2012; 13:
191–211.
3. Misiak-Galazka M, Wolska H, Galazka A, Kwiek B, Rudnicka L. General
characteristics and comorbidities in patients with palmoplantar
pustulosis. Acta Dermatovenerol Croat. 2018;26(2):109–18
4. Marzano AV, Cugno M, Trevisan V et al. Role of inflammatory cells,
cytokines and matrix metalloproteinases in neutrophil-mediated skin
diseases. Clin Exp Immunol 2010; 162: 100–107.
5. Guenova E, Teske A, Fehrenbacher B et al. Interleukin 23 expression
in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch
Dermatol 2011; 147: 1203–1205.
6. Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H.
Patients with palmoplantar pustulosis have increased IL-17 and IL-22
levels both in the lesion and serum. Exp Dermatol 2011; 20: 845–847.
7. Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a
retrospective review of patient characteristics, comorbidities and
therapy in 103 patients. Br J Dermatol 2011; 165:1244–1250.
8. Kameyama H, Akagane Y, Kawada A, Tezuka T. A case of palmoplantar
pustulosis associated with pyoderma gangrenosum. Hifunokagaku 2003; 2:
526–531.
9. Ogasawara K. Pyoderma gangrenosum associated with palmoplantar
pustulosis (original title in Japanese). Nihon Rinsho Hifuka Ikai Zasshi
2006; 23: 136–138
10. Ohtsuka M and Yamamoto T. Association of pyoderma gangrenosum and
palmoplantar pustulosis: A case report and review of the previous works.
Journal of Dermatology 2014; 41: 732–735
11. Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality,
and disease associations of pyoderma gangrenosum in the United Kingdom:
a retrospective cohort study. J Invest Dermatol 2012; 132:2166–70
12. Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar
pustulosis: a clinical and immunohistological study. Br J Dermatol 1998;
138:390–8.
13. Burden AD, Kemmett D. The spectrum of nail involvement in
palmoplantar pustulosis. Br J Dermatol 1996;134;1079–82.
14. Hiraiwa T, Yamamoto T. Nail involvement associated with palmoplantar
pustulosis. Int J Dermatol. 2017;56(2): e28–9
15. Nguyen MT, Borchers A, Selmi C, et al. The SAPHO syndrome. Semin
Arthritis Rheum 2012; 42:254–65
16. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma
gangrenosum: a review and update on new therapies. J Am Acad Dermatol
2010; 62: 646–654.
17. Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment
of palmoplantar pustulosis. Br J Dermatol 2010; 163:1116–18.
Figures:
Figure 1(a) (10X) H & E stain
showing hemorrhagic ulcer (black arrows) adjoining an intact epidermis
with large necrotizing suppurative dermal inflammation (white arrows)
(b) (40X) H & E stain showing dense neutrophilic infiltrate in the
dermis with extravasation of Red blood cells (c) (40X) H & E stain (red
arrows) showing endothelial swelling with neutrophilic infiltration of
blood vessel wall
Figure 2 (a and b) showing irregular undermined ulcer with atrophic
plaque on dorsum of left foot, (c and d) erythematous plaque with yellow
brown crust, (e and f) onycholysis and subungual hyperkeratosis, (g and
h) 1 week after starting treatment, (I and j) 4 weeks after starting
treatment and (m, n, o and p) 9 months after stopping the treatment
Figure 3(a) (10X) H & E stain showing hyperkeratosis with parakeratosis
with munro’s micro abscess (black arrows) with hypogranular layer (white
arrow) with psoriasiform hyperplasia of epidermis (red arrow) (b) (10X)
H & E stain showing munro microabscess with underlying hypogranular
layer (c) 100X magnification showing neutrophil and neutrophilic dusts
in stratum corneum (munro microabsess)